Trials / Withdrawn
WithdrawnNCT06398080
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
Real-World Patient Characteristics, Treatment Patterns, and Outcomes Among Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) Treated With Aflibercept 8 mg in the United States
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to observe the patient's clinical care and how EYLEA® HD is used as a treatment in real-world settings. Patients are asked to join the study because they have either neovascular age-related macular degeneration (nAMD/wet age-related macular degeneration \[AMD\]) or diabetic macular edema (DME). Patients cannot have used EYLEA® HD in the past and the doctor must be planning to treat nAMD or DME with a new prescription of EYLEA® HD (aflibercept 8 mg).
Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Wet Age-related Macular Degeneration (AMD)
- Diabetic Macular Edema (DME)
- Visual Impairment
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aflibercept 8 mg | No intervention will be provided to study patients. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and following approved clinical guidelines. |
Timeline
- Start date
- 2024-12-12
- Primary completion
- 2028-01-03
- Completion
- 2029-01-03
- First posted
- 2024-05-03
- Last updated
- 2024-11-25
Source: ClinicalTrials.gov record NCT06398080. Inclusion in this directory is not an endorsement.